Search company, investor...

Predict your next investment

Non-Profit Foundation
virtualtrials.com

Investments

2

Portfolio Exits

2

About Musella Foundation for Brain Tumor Research & Information

The Musella Foundation For Brain Tumor Research & Information is a 501(c)3 non- profit organization dedicated to speeding up the search for the cure of brain tumors, as well as helping families deal with the diagnosis of brain cancer, by funding innovative brain tumor research, education, advocacy and support for families that are dealing with brain tumors and organizing the brain tumor community to work together as an army to fight the disease.

Headquarters Location

1100 Peninsula Blvd

Hewlett, New York, 11557,

United States

516-295-4740

Want to inform investors similar to Musella Foundation for Brain Tumor Research & Information about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Musella Foundation for Brain Tumor Research & Information News

Oncoceutics Receives ONC201 Research Grant From Musella Foundation For Brain Tumor Research & Information - Oncoceutics

Sep 29, 2014

CONTACT Oncoceutics Receives ONC201 Research Grant From Musella Foundation For Brain Tumor Research & Information Hummelstown, PA (June 18, 2014) – Oncoceutics, Inc., a biotechnology company focused on developing innovative oncology treatments addressing major unmet medical needs to advance cancer care, announced that the Musella Foundation For Brain Tumor Research & Information, Inc, has awarded Oncoceutics a research grant to study ONC201 in glioblastoma multiforme (GBM), the most aggressive form of human brain cancer.The funded research project entitled “Target Identification of ONC201, a First-in-Class Drug to Treat Glioblastoma” aims to enhance the molecular understanding of how ONC201 kills brain tumor cells. Preclinical studies by several leading investigators indicate that ONC201 is highly effective at treating GBM in both cell culture and in animal models, including refractory primary patient samples and cancer stem cells. The Musella Foundation grant will fund laboratory studies assessing GBM cells that trigger strong antitumor effects in response to ONC201. “I am elated to receive support for this important project from the Musella Foundation, which underscores the high therapeutic potential that ONC201 represents for patients with GBM,” said Joshua Allen, Director of Development, Co-Inventor of ONC201, and Principal Investigator of the Musella Foundation grant. “These funds will yield key information about how this unique molecule is effective in GBM, which can help to both guide how patients with this devastating disease are treated with this new therapy and how future drugs could be created to be even more effective and safe.” “The Executive Board and Medical Advisors at the Musella Foundation were extremely impressed with this project for ONC201,” said Al Musella, DPM, President of the Musella Foundation. We are optimistic that ONC201 could be a major breakthrough in the treatment of brain tumors.” On February 28, the U.S. Food and Drug Administration accepted the company’s Investigational New Drug (IND) application for the Phase I/II trial of ONC201, and the company expects to begin clinical trials during the third quarter of 2014. Patients with advanced GBM will be assessed as part of these trials as a result of the strong pre-clinical data suggesting that ONC201 is likely to be effective at treating GBM. About The Musella Foundation The Musella Foundation For Brain Tumor Research & Information, Inc, is a 501(c)3 nonprofit public charity dedicated to helping brain tumor patients through emotional and financial support, education, advocacy and raising money for brain tumor research. Funds to support research grants were raised from the National Walk To End Brain Tumors (www.WalkToEndBrainTumors.org). The Musella Foundation has been involved in supporting research, regulatory approval, and reimbursement strategies for several of the cornerstones of GBM treatment, including Temodar, Avastin, Gliadel, and NovoCure TTF. About Oncoceutics Oncoceutics, Inc. is a drug discovery and development company targeting the most potent suppressor pathways in human cancer. The company’s leadership team represents a group of drug development executives with unparalleled success in the industry. Central to Oncoceutics’ scientific and technology base is a focus on drug discovery that engages natural potent tumor suppressor pathways. The first lead compound that came out of this program is ONC201, a small molecule that possesses significant anti-tumor activity in a number of different types of human cancer through a unique mechanism of action. On February 28, the U.S. Food and Drug Administration accepted the company’s Investigational New Drug (IND) application for the Phase I/II trial of ONC201, and the company expects to begin clinical trials during the third quarter of 2014. Contact: Lee Schalop, Chief Business Officer, lee.schalop@oncoceutics.com. Safe Harbor Forward-Looking Statements To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company’s development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Photostream

Musella Foundation for Brain Tumor Research & Information Investments

2 Investments

Musella Foundation for Brain Tumor Research & Information has made 2 investments. Their latest investment was in Oncoceutics as part of their Grant on June 6, 2014.

CBI Logo

Musella Foundation for Brain Tumor Research & Information Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/18/2014

Grant

Oncoceutics

Yes

1

7/17/2012

Grant - IV

Subscribe to see more

Subscribe to see more

10

Date

6/18/2014

7/17/2012

Round

Grant

Grant - IV

Company

Oncoceutics

Subscribe to see more

Amount

New?

Yes

Subscribe to see more

Co-Investors

Sources

1

10

Musella Foundation for Brain Tumor Research & Information Portfolio Exits

2 Portfolio Exits

Musella Foundation for Brain Tumor Research & Information has 2 portfolio exits. Their latest portfolio exit was Oncoceutics on January 08, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/8/2021

Acquired

$99M

5

4/13/2017

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/8/2021

4/13/2017

Exit

Acquired

IPO

Companies

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Subscribe to see more

Sources

5

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.